1. Niemialtowski MG, Toka FN, Malicka E, Gierynska M, de Faundez IS, Schollenberger A. Controlling orthopoxvirus infections—200 years after Jenner's revolutionary immunization. Arch Immunol Ther Exp 1996; 44:373-378.

2. Mastrangelo MJ, Eisenlohr LC, Gomella L, Lattime EC. Poxvirus vectors: Orphaned and underappreciated. J Clin Invest 2000; 105(8):1031-1034.

3. Esposito JJ, FennerF. Poxviruses. In: Knipe DM, Howley PM, Eds. Fields Virology. Philadelphia: Lippincott Williams & Wilkins, 2001:2885-2921.

4. Baxby D. Vaccinia virus. In: Quinnan GV, Ed. Vaccinia Viruses as Vectors for Vaccine Antigens. New York>: Elsevier, 1985:3-8.

5. Fenner F, Wittek R, Dumbell KR. Vaccinia Virus: The Tool for Smallpox Eradication. The Orthopoxviruses. New York: Academic Press, 1989:143-170.

6. Moss B. Vaccinia virus. A tool for research and vaccine development. Science 1991; 252:1662-1667.

7. Smith GL, Moss B. Infectious poxvirus vectors have capacity for at least 25,000 base pairs of foreign DNA. Gene 1983; 25: 21-28.

8. Moss B. Poxvirus vectors: cytoplasmic expression of transferred genes. Curr Opin Genet Dev 1992; 3:86-90.

9. Bartlett DL. Vaccinia virus. Monogr Virol 2001; 22:129-158.

10. Zeh HJ, Bartlett DL. Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers. Cancer Gene Ther 2002; 9(12):1001-1012.

11. Moss B. Poxviridae: The viruses and their replication. In: Fields BN, Knipe DM, Howley PM, Eds. Fields Virology. Philadelphia: Lippincott-Raven, 1996:2637-2671.

Sutter G, Moss B. Novel vaccinia vector derived from the host range restricted and highly attenuated MVA strain of vaccinia virus. Dev Biol Stand 1995; 84:195-200. Goebel SJ, Johnson GP, Perkus ME, Davis SW, Winslow JP, Paoletti E. The complete DNA sequence of vaccinia virus. Virology 1990; 179(1):247-266.

Antoine G, Scheiflinger F, Dorner F, Falkner FG. The complete genomic sequence of the modified vaccinia Ankara strain: Comparison with other orthopoxviruses. Virology 1998; 242(2):365-396.

Dubochet J, Adrian M, Richter K, Garces J, Wittek R. Structure of intracellular mature vaccinia virus observed by cryoele-ctron microscopy. J Virol 1994; 68(3):1935-1941. Smith GL, Vanderplasschen A. Extracellular enveloped vaccinia virus: Entry, egress, and evasion. In: Enjuanes A, Ed. Coronaviruses and Arteriviruses. New York: Plenum Press, 1998:395-414.

Vanderplasschen A, Hollinshead M, Smith GL. Intracellular and extracellular vaccinia virions enter cells by different mechanisms. J Gen Virol 1998; 79(Pt 4):877-887. Vanderplasschen A, Smith GL. A novel virus binding assay using confocal microscopy: Demonstration that the intracellu-lar and extracellular vaccinia virions bind to different cellular receptors. J Virol 1997; 71(5):4032-4041. Betakova T, Wolffe EJ, Moss B. Membrane topology of the vaccinia virus A17L envelope protein. Virology 1999; 261(2): 347-356.

Wolffe EJ, Moore DM, Peters PJ, Moss B. Vaccinia virus A17L open reading frame encodes an essential component of nascent viral membranes that is required to initiate morphogenesis. J Virol 1996; 70(5):2797-2808. Sanderson CM, Hollinshead M, Smith GL. The vaccinia virus A27L protein is needed for the microtubule-dependent transport of intracellular mature virus particles. J Gen Virol 2000; 81(Pt 1):47-58.

Chung CS, Hsiao JC, Chang YS, Chang W. A27L protein mediates vaccinia virus interaction with cell surface heparan sulfate. J Virol 1998; 72:1577-1585. Sodeik B, Cudmore S, Ericsson M, Esteban M, Niles EG, Griffiths G. Assembly of vaccinia virus: Incorporation of p14 and p32 into the membrane of the intracellular mature virus. J Virol 1995; 69(6):3560-3574.

Hsiao JC, Chung CS, Chang W. Vaccinia virus envelope D8L protein binds to cell surface chondroitin sulfate and mediates the adsorption of intracellular mature virions to cells. J Virol 1999; 73(10):8750-8761.

Wallengren K, Risco C, Krijnse-Locker J, Esteban M, Rodriguez D. The A17L gene product of vaccinia virus is exposed on the surface of IMV. Virology 2001; 290(1):143-152. Law M, Smith GL. Antibody neutralization of the extracellular enveloped form of vaccinia virus. Virology 2001; 280(1): 132-142.

Galmiche MC, Rindisbacher L, Wels W, Wittek R, Buchegger F. Expression of a functional single chain antibody on the surface of extracellular enveloped vaccinia virus as a step towards selective tumour cell targeting. J Gen Virol 1997; 78: 3019-3027.

Katz E, Wolffe EJ, Moss B. The cytoplasmic and transmembrane domains of the vacinia virus B5R protein target a chi-meric human immunodeficiency virus type 1 glycoprotein to the outer envelope of nascent vaccinia virions. J Virol 1997; 71(4):3178-3187.

Salzman NP. The rate of formation of vaccinia deoxyribonucleic acid and vaccinia virus. Virology 1960; 10:150-152. Beaud G. Vaccinia virus DNA replication: A short review. Biochimie 1995; 77(10):774-779.

31. Broyles SS, Liu X, Zhu M, Kremer M. Transcription factor YY1 is a vaccinia virus late promoter activator. J Biol Chem 1999; 274(50):35662-35667.

32. Zhu M, Moore T, Broyles SS. A cellular protein binds vaccinia virus late promoters and activates transcription in vitro. J Virol 1998; 72(5):3893-3899.

33. Sodeik B, Krijnse-Locker J. Assembly of vaccinia virus revisited: De novo membrane synthesis or acquisition from the host. Trends Microbiol 2002; 10(1):15-24.

34. Blasco R, Sisler JR, Moss B. Dissociation of progeny vaccinia virus from the cell membrane is regulated by a viral envelope glycoprotein: Effect of a point mutation in the lectin homology domain of the A34R gene. J Virol 1993; 67(6):3319-3325.

35. Yuen L, Moss B. Oligonucleotide sequence signaling tran-scriptional termination of vaccinia virus early genes. Proc Natl Acad Sci USA 1987; 84(18):6417-6421.

36. Buller RM, Smith GL, Cremer K, Notkins AL, Moss B. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative pheno-type. Nature 1985; 317:813-815.

37. Buller RML, Chakrabarti S, Cooper JA, Twardzik DR, Moss B. Deletion of the vaccinia virus growth factor gene reduces virus virulence. J Virol 1988; 62:866-874.

38. Fathi Z, Dyster LM, Seto J, Condit RC, Niles EG. Intragenic and intergenic recombination between temperature-sensitive mutants of vaccinia virus. J Gen Virol 1991; 72(Pt 11): 2733-2737.

39. Davison AJ, Moss B. Structure of vaccinia virus early promoters. J Mol Biol 1989; 210:749-769.

40. Davison AJ, Moss B. Structure of vaccinia virus late promoters. J Mol Biol 1989; 210(4):771-784.

41. Chakrabarti S, Sisler JR, Moss B. Compact, synthetic, vaccinia virus early/late promoter for protein expression. BioTechniques 1997; 23:1094-1097.

42. Earl PL, Moss B. Expression of proteins in mammalian cells using vaccinia viral vectors. In: Ausubel FM, Kinston R, Kingston RE, Moore DD, Seidman JG, Smith JA, et al, Eds. Current Protocols in Molecular Biology. New York: Greene/ Wiley Interscience, 1998:16.

43. Boyle DB, Coupar BE. A dominant selectable marker for the construction of recombinant poxviruses. Gene 1988; 65(1): 123-128.

44. Perkus ME, Limbach K, Paoletti E. Cloning and expression of foreign genes in vaccinia virus, using a host range selection system. J Virol 1989; 63(9):3829-3836.

45. Panicali D, Paoletti E. Construction of poxviruses as cloning vectors: Insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc Natl Acad Sci USA 1982; 79(16):4927-4931.

46. Mackett M, Smith GL, Moss B. Vaccinia virus: A selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci USA 1982; 79(23):7415-7419.

47. Cochran MA, Mackett M, Moss B. Eukaryotic transient expression system dependent on transcription factors and regulatory DNA sequences of vaccinia virus. Proc Natl Acad Sci USA 1985; 82(1):19-23.

48. Tsung K, Yim JH, Marti W, Buller RM, Norton JA. Gene expression and cytopathic effect of vaccinia virus inactivated by psoralen and long-wave UV light. J Virol 1996; 70(1): 165-171.

49. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci USA 1996; 93:11341-11348.

50. Lane JM, Millar JD. Risks of smallpox vaccination complications in the United States. Am J Epidemiol 1971; 93(4): 238-240.

51. Robinson MJ, Muragasu R, Thong YH, Chen ST. A fatal case of progressive vaccinia—Clinical and pathological studies. Aust Paediatr J 1977; 13(2):125-130.

52. Turkel SB, Overturf GD. Vaccinia necrosum complicating im-munoblastic sarcoma. Cancer 1977; 40(1):226-233.

53. Keane JT, James K, Blankenship ML, Pearson RW. Progressive vaccinia associated with combined variable immunodeficiency. Arch Dermatol 1983; 119(5):404-408.

54. Gurvich EB, Vilesova IS. Vaccinia virus in postvaccinal encephalitis. Acta Virol 1983; 27(2):154-159.

55. Enserink M. Public health. Treating vaccine reactions: Two lifelines, but no guarantees. Science 2002; 298(5602):2313.

56. Enserink M. Bioterrorism. In search of a kinder, gentler vaccine. Science 2002; 296(5573):1594.

57. Peplinski GR, Tsung K, Casey MJ, Meko JB, Fredrickson TN, Buller RM, et al. In vivo murine tumor gene delivery and expression by systemic recombinant vaccinia virus encoding interleukin-1 beta. Cancer J Sci Am 1996; 2(1):21.

58. Puhlmann M, Brown CK, Gnant M, Huang J, Libutti SK, Alexander HR, et al. Vaccinia as a vector for tumor directed gene therapy: Biodistribution of a thymidine kinase deleted mutant. Cancer Gene Ther 2000; 7(1):66-73.

59. Whitman ED, Tsung K, Paxson J, Norton JA. In vitro and in vivo kinetics of recombinant vaccinia virus cancer-gene therapy. Surgery 1994; 116(2):183-188.

60. Mastrangelo MJ, Maguire HC, Eisenlohr LC, Laughlin CE, Monken CE, McCue PA, et al. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther 1998; 6(5):409-422.

61. Smith GL, Symons JA, Khanna A, Vanderplasschen A, Al-cami A. Vaccinia virus immune evasion. Immunol Rev 1997; 159:137-154.

62. Smith GL, Vanderplasschen A, Law M. The formation and function of extracellular enveloped vaccinia virus. J Gen Virol 2002; 83(Pt 12):2915-31.

63. Fenner F, Wittek R, Dumbell KR. The Pathogenesis, Pathology, and Immunology of Orthopoxvirus Infections. The Orthopoxviruses. New York: Academic Press, 1989:85-141.

64. McCart JA, Puhlmann M, Lee J, Hu Y, Libutti SK, Alexander HR, et al. Complex interactions between the replicating onco-lytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression. Gene Ther 2000; 7:1217-1223.

65. Alcami A, Symons JA, Smith GL. The vaccinia virus soluble alpha/beta interferon (IFN) receptor binds to the cell surface and protects cells from the antiviral effects of IFN. J Virol 2000; 74(23):11230-11239.

66. Colamonici OR, Domanski P, Sweitzer SM, Larner A, Buller RM. Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon alpha transmembrane signaling. J Biol Chem 1995; 270(27):15974-15978.

67. Alcami A, Smith GL. The vaccinia virus soluble interferon-gamma receptor is a homodimer. J Gen Virol 2002; 83(Pt 3): 545-549.

68. Seet BT, McFadden G. Viral chemokine-binding proteins. J Leukoc Biol 2002; 72(1):24-34.

69. Alcami A, Symons JA, Collins PD, Williams TJ, Smith GL. Blockade of chemokine activity by a soluble chemokine binding protein from vaccinia virus. J Immunol 1998; 160(2): 624-633.

70. Mahalingam S, Karupiah G. Modulation of chemokines by poxvirus infections. Curr Opin Immunol 2000; 12(4): 409-412.

71. Symons JA, Alcami A, Smith GL. Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell 1995; 81(4):551-560.

72. Najarro P, Traktman P, Lewis JA. Vaccinia virus blocks gamma interferon signal transduction: Viral VH1 phosphatase reverses Stat1 activation. J Virol 2001; 75(7):3185-3196.

73. Adam BL, Vlahou A, Semmes OJ, Wright GL. Proteomic approaches to biomarker discovery in prostate and bladder cancers. Proteomics 2001; 1(10):1264-1270.

74. Smith VP, Bryant NA, Alcami A. Ectromelia, vaccinia and cowpox viruses encode secreted interleukin-18-binding proteins. J Gen Virol 2000; 81(Pt 5):1223-1230.

75. Calderara S, Xiang Y, Moss B. Orthopoxvirus IL-18 binding proteins: Affinities and antagonist activities. Virology 2001; 279(1):22-26.

76. Angelini G, Gardella S, Ardy M, Ciriolo MR, Filomeni G, Di Trapani G, et al. Antigen-presenting dendritic cells provide the reducing extracellular microenvironment required for T lymphocyte activation. Proc Natl Acad Sci USA 2002; 99(3): 1491-1496.

77. Novick D, Kim SH, Fantuzzi G, Reznikov LL, Dinarello CA, Rubinstein M. Interleukin-18 binding protein: A novel modulator of the Th1 cytokine response. Immunity 1999; 10(1): 127-136.

78. Engelstad M, Howard ST, Smith GL. A constitutively expressed vaccinia gene encodes a 42-kDa glycoprotein related to complement control factors that forms part of the extracellular virus envelope. Virology 1992; 188(2):801-810.

79. Bowie A, Kiss-Toth E, Symons JA, Smith GL, Dower SK, O'Neill LA. A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling. Proc Natl Acad Sci USA 2000; 97(18):10162-10167.

80. Howard ST, Chan YS, Smith GL. Vaccinia virus homologues of the Shope fibroma virus inverted terminal repeat proteins and a discontinuous ORF related to the tumor necrosis factor receptor family. Virology 1991; 180(2):633-647.

81. Smith GL, Howard ST, Chan YS. Vaccinia virus encodes a family of genes with homology to serine proteinase inhibitors. J Gen Virol 1989; 70(Pt 9):2333-2343.

82. Albores-SaavedraJ, Heffess C, HrubanRH, KlimstraD, Long-necker D. Recommendations for the reporting of pancreatic specimens containing malignant tumors. The Association of Directors of Anatomic and Surgical Pathology. Am J Clin Pathol 1999; 111(3):304-307.

83. Van den Broek M, Bachmann MF, Kohler G, Barner M, Escher R, Zinkernagel R, et al. IL-4 and IL-10 antagonize IL-12-mediated protection against acute vaccinia virus infection with a limited role of IFN-gamma and nitric oxide synthetase 2. J Immunol 2000; 164(1):371-378.

84. Deonarain R, Alcami A, Alexiou M, Dallman MJ, Gewert DR, Porter AC. Impaired antiviral response and alpha/beta interferon induction in mice lacking beta interferon. J Virol 2000; 74(7):3404-3409.

85. Grace JT, Mirand EA. Yaba virus infection in humans. Exp Med Surg 1965; 23:213-216.

86. Hu Y, Lee J, McCart A, Xu H, Moss B, Alexander HR, et al. Yaba like disease virus: An alternating replicating pox vector for cancer gene therapy. J Virol 2001; 75(21):10300-10308.

87. Paoletti E. Applications of pox virus vectors to vaccination: An update. Proc Natl Acad Sci USA 1996; 93:11349-11353.

88. Sharma DP, Ramsay AJ, Maguire DJ, Rolph MS, Ramshaw IA. Interleukin-4 mediates down regulation of antiviral cyto-kine expression and cytotoxic T-lymphocyte responses and exacerbates vaccinia virus infection in vivo. J Virol 1996; 70(10):7103-7107.

89. Alvarez-Vallina L, Agha-Mohammadi S, Hawkins RE, Russell SJ. Pharmacological control of antigen responsiveness in genetically modified T lymphocytes. J Immunol 1997; 159(12):5889-5895.

Sandvik T, Tryland M, Hansen H, Mehl R, Moens U, Olsvik O, et al. Naturally occurring orthopoxviruses: Potential for recombination with vaccine vectors. J Clin Microbiol 1998; 36:2542-2547.

Dorozynski A, Anderson A. Deaths in vaccine trials trigger French inquiry. Science 1991; 252:501-502. Wang M, Bronte V, Chen PW, Gritz L, Panicali D, Rosenberg SA, et al. Active immunotherapy of cancer with a nonreplicat-ing recombinant fowlpox virus encoding a model tumor-associated antigen. J Immunol 1995; 154:4685-4692. Li Y, Hall RL, Moyer RW. Transient, nonlethal expression of genes in vertebrate cells by recombinant entomopoxviruses. J Virol 1997; 71(12):9557-9562.

Blanchard TJ, Alcami A, Andrea P, Smith GL. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: Implications for use as a human vaccine. J Gen Virol 1998; 79: 1159-1167.

Tsung K, Yim JH, Mari W, Buller RML, Norton JA. Gene expression and cytopathic effect of chemically inactivated vaccinia virus. J Virol 1996.

Plautz G, Nabel EG, Nabel GJ. Selective elimination of recombinant genes in vivo with a suicide retroviral vector. The New Biologist 1991; 3(7):709-715.

Flexner C, Moss B, London WT, Murphy BR. Attenuation and immunogenicity in primates of vaccinia virus recombinants expressing human interleukin-2. Vaccine 1990; 8:17-22. Ramshaw A, Andrew ME, Phillips SM, Boyle DB, Coupar BEH. Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection. Nature 1987; 329:545-546. Kohonen-Corish MR, King NJ, Woodhams CE, Ramshaw IA. Immunodeficient mice recover from infection with vaccinia virus expressing interferon-gamma. Eur J Immunol 1990; 20: 157-161.

McCart JA, Ward JM, Lee J, Hu Y, Alexander HR, Libutti SK, et al. Systemic cancer therapy with a tumor selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 2001; 61:8751-8757. Baxby D. Smallpox vaccination techniques: From knives and forks to needles and pins. Vaccine 2002; 20(16):2140-9. Demkowicz WE, Littaua RA, Wang J, Ennis FA. Human cytotoxic T-cell memory: Long-lived responses to vaccinia virus. J Virol 1996; 70(4):2627-2631.

Lattime EC, Lee SS, Eisenlohr LC, Mastrangelo MJ. In situ cytokine gene transfection using vaccinia virus vectors. Semin Oncol 1996; 23(1):88-100.

Rosenberg SA, Blaese RM, Brenner MK, Deisseroth AB, Led-ley FD, Lotze MT, et al. Human gene marker/therapy clinical protocols. Hum Gene Ther 1999; 10(18):3067-3123. Wallack MK, Sivanandham M, Balch CM, Urist MM, Bland KI, Murray D, et al. Surgical adjuvant active specific immuno-therapy for patients with stage III melanoma: The final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg 1998; 187(1):69-77.

Hersey P, Edwards A, Coates A, Shaw H, McCarthy W, Milton G. Evidence that treatment with vaccinia melanoma cell ly-sates (VMCL) may improve survival of patients with stage II melanoma. Treatment of stage II melanoma with viral lysates. Cancer Immunol Immunother 1987; 25(3):257-265. Hersey P. Evaluation of vaccinia viral lysates as therapeutic vaccines in the treatment of melanoma. Ann NY Acad Sci 1993; 690:167-77.

Eder JP, Kantoff PW, Roper K, Xu GX, Bubley GJ, Boyden J, et al. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res 2000; 6:1632-1638.

109. Marshall JL, Hoyer RJ, Toomey MA, Faraguna K, Chang P, Richmond E, et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 2000; 18(23):3964-73.

110. Greiner JW, Zeytin H, Anver MR, Schlom J. Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. Cancer Res 2002; 62(23): 6944-51.

111. Hernaiz Driever P, Rabkin SD. Replication-competent viruses for cancer therapy. Monogr Virol 2001; 22:1-187.

112. Kirn D, Scanlon K. Virotherapy for cancer—current status, hurdles and future directions. Cancer Gene Ther 9(12): 959-1067.

113. Gnant MFX, Puhlmann M, Alexander HR, Bartlett DL. Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor specific gene expression and prolongation of survival in mice. Cancer Res 1999; 59: 3396-3404.

114. Mukherjee S, Haenel T, Himbeck R, Scott B, Ramshaw I, Lake RA, et al. Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: Persistent transgene expression despite antibody generation. Cancer Gene Ther 2000; 7: 663-670.

115. Naik A, McCart JA, Xu H, Kivlen MH, Langham G, Emanuel C, et al. Intravenous and isolated limb perfusion delivery of a tumor selective vaccinia virus mutant in non-human primates. Mol Ther 2001; 3(5):s303-s304.

116. Gnant M, Noll L, Irvine KR, Puhlmann M, Terril R, Alexander HR, et al. Tumor specific gene delivery using recombinant vaccinia virus in a rabbit model of unresectable liver metasta-ses—Pattern of gene expression, vector elimination and immune response. J Natl Cancer Inst 1999; 91(20):1744-1750.

117. Peplinski GR, Tsung K, Casey MJ, Meko JB, Fredrickson TN, Buller RML, et al. In vivo murine tumor gene delivery and expression by systemic recombinant vaccinia virus encoding interleukin-1beta. Cancer J 1996; 2:21-27.

118. Goede V, Schmidt T, Kimmina S, Kozian D, Augustin HG. Analysis of blood vessel maturation processes during cyclic ovarian angiogenesis. Lab Invest 1998; 78(11):1385-1394.

119. Roenigk HH, Deodhar S, Burdick K. Immunotherapy of malignant melanoma with vaccinia virus. Arch Dermatol 1974; 109(5):668-673.

120. Israel RM. Treatment of warts by vaccination. Arch Dermatol 1969; 100:222-223.

121. Mastrangelo MJ, Maguire HC, Lattime EC. Intralesional vaccinia/GM-CSF recombinant virus in the treatment of metastatic melanoma. Adv Exp Med Biol 2000; 465:391-400.

122. De Clercq E. Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections. Clin Microbiol Rev 2001; 14:382-397.

123. De Clercq E. Cidofovir in the treatment of poxvirus infections. Antiviral Res 2002; 55:1-13.

124. Smee DF, Bailey KW, Wong MH, Sidwell RW. Effects of cidofovir on the pathogenesis of a lethal vaccinia virus respiratory infection in mice. Antiviral Res 2001; 52:55-62.

125. Traktman P, Liu K, DeMasi J, Rollins R, Jesty S, Unger B. Elucidating the essential role of the A14 phosphoprotein in vaccinia virus morphogenesis: Construction and characterization of a tetracycline-inducible recombinant. J Virol 2000; 74(8):3682-3695.

126. Sanda MG, Smith DC, Charles LG, Hwang C, Pienta KJ, Schlom J, et al. Recombinant vaccinia-PSA (Prostvac) can induce a prostate-specific immune response in androgen-mod-ulated human prostate cancer. Urology 1999; 53:260-266. 136.

127. Conry RM, Allen KO, Lee S, Moore SE, Shaw DR, LoBuglio AF. Human autoantibodies to carcinoembryonic antigen (CEA) induced by a vaccinia-CEA vaccine. Clin Cancer Res 2000; 6(1):34-41.

128. Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, 137. Schlom J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Can- 138. cer Inst 1995; 87:982-990.

129. Graham BS, Gorse GJ, Schwartz DH, Keefer MC, McElrath MJ, Matthews TJ, et al. Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National 139. Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network. J Infect Dis 1994; 170:782-786.

130. Adams M, Borysiewicz L, Fiander A, Man S, Jasani B, Navabi 140. H, et al. Clinical studies of human papilloma vaccines in preinvasive and invasive cancer. Vaccine 2001; 19:2549-2556.

131. Kanesa-thasan N, Smucny JJ, Hoke CH, Marks DH, Konishi E, Kurane I, et al. Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese en- 141. cephalitis virus—Poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans. Vaccine 2000; 19:483-491.

132. McClain DJ, Summers PL, Harrison SA, Schmaljohn AL, Schmaljohn CS. Clinical evaluation of a vaccinia-vectored 142. Hantaan virus vaccine. J Med Virol 2000; 60:77-85.

133. McAneny D, Ryan CA, Beazley RM, Kaufman HL. Results of a Phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal 143. cancer. Ann Surg Oncol 1996; 3(5):495-500.

134. Borysiewicz LK, Fiander A, Nimako M, Man S, Wilkinson GW, Westmoreland D, et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 144. proteins as immunotherapy for cervical cancer. Lancet 1996; 347:1523-1527. 145.

135. Picard O, Achour A, Bernard J, Halbreich A, Bizzini B, Boyer V, et al. A 2-year follow-up of an anti-HIV immune reaction in HIV-1 gp160-immunized healthy seronegative humans: Evidence for persistent cell-mediated immunity. J Acquir Immune Defic Syndr 1992; 5:539-546.

Sidwell RW, Allen LB, Khare GP, Huffman JH, Witkowski JT, Simon LN, et al. Effect of 1-beta-D-ribofuranosyl1-1,2,4 -triazole-3-carboxamide (virazole, ICN 1229) on herpes and vaccinia keratitis and encephalitis in laboratory animals. Anti-microb Agents Chemother 1973; 3:242-246. De Clercq E, De Somer P. Effect of interferon, polyacrylin acid, and polymethacrylic acid on tail lesions on mice infected with vaccinia virus. Appl Microbiol 1968; 16:1314-1319. De Clercq E, Luczak M, Shugar D, Torrence PF, Waters JA, Witkop B. Effect of cytosine, arabinoside, iododeoxyuridine, ethyldeoxyuridine, thiocyanatodeoxyuridine, and ribavirin on tail lesion formation in mice infected with vaccinia virus. Proc Soc Exp Biol Med 1976; 151:487-490. De Clercq E, Bergstrom DE, Holy A, Montgomery JA. Broad-spectrum antiviral activity of adenosine analogues. Antiviral Res 1984; 4:119-133.

Tseng CK, Marquez VE, Fuller RW, Goldstein BM, Haines DR, McPherson H, et al. Synthesis of 3-deazaneplanocin A, a powerful inhibitor of S-adenosylhomocysteine hydrolase with potent and selective in vitro and in vivo antiviral activities. J Med Chem 1989; 32:1442-1446.

De Clercq E, Holy A, Rosenberg I. Efficacy of phosphonyl-methoxyalkyl derivatives of adenine in experimental herpes simplex virus and vaccinia virus infections in vivo. Antimicrob Agents Chemother 1989; 33:185-191. Neyts J, De Clercq E. Efficacy of (S)-1-(3-hydroxy-2-phos-phonylmethoxypropyl)cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice. J Med Virol 1993; 41:242-246. Neyts J, De Clercq E. Efficacy of 2-amino-7-(1,3-dihydroxy-2-propoxymethyl)purine for treatment of vaccinia virus (or-thopoxvirus) infections in mice. Antimicrob Agents Chemo-ther 2001; 45:84-87.

Moss B. Vaccinia Virus. A tool for research and vaccine development. Science 1991; 252:1662-1667. Wills VL, Boorer CJ, Foster HM, Hersey P, Kesson A. Vaccinia necrosum: A forgotten disease. Aust NZJ Surg 2000; 70: 149-150.

0 0

Post a comment